Lymphoma News and Research

RSS
Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
VAV1 gene mutations may promote growth of T-cell tumors in laboratory mice

VAV1 gene mutations may promote growth of T-cell tumors in laboratory mice

New radioimmunotherapy effectively reverses resistance to lymphoma therapy

New radioimmunotherapy effectively reverses resistance to lymphoma therapy

CAR T cell therapy can predict treatment outcomes in patients with large B-cell lymphoma

CAR T cell therapy can predict treatment outcomes in patients with large B-cell lymphoma

Memory training for the immune system

Memory training for the immune system

Eliminating tumors with engineered ‘off-the-shelf’ therapeutic T cells

Eliminating tumors with engineered ‘off-the-shelf’ therapeutic T cells

A genetic link discovered to predict treatment response for patients with rare, aggressive cancer

A genetic link discovered to predict treatment response for patients with rare, aggressive cancer

Clinical trial shows CAR-T cell therapy can be used for treating Hodgkin lymphoma

Clinical trial shows CAR-T cell therapy can be used for treating Hodgkin lymphoma

New approach is more effective in treating certain blood cancers

New approach is more effective in treating certain blood cancers

Reactivating divergent signaling pathways to enhance cancer treatment

Reactivating divergent signaling pathways to enhance cancer treatment

Dual inhibitor therapy may be safer for patients with chronic lymphocytic leukemia

Dual inhibitor therapy may be safer for patients with chronic lymphocytic leukemia

New technology generates immune response by delivering antigens to APCs in the spleen

New technology generates immune response by delivering antigens to APCs in the spleen

ASC-enriched fat grafts for breast augmentation could produce superior results

ASC-enriched fat grafts for breast augmentation could produce superior results

Engineered T-cells attack solid-tumor cancer cells from humans and mice

Engineered T-cells attack solid-tumor cancer cells from humans and mice

Genome sequencing reveals signposts in DNA for cancer, disease risk

Genome sequencing reveals signposts in DNA for cancer, disease risk

A metabolic enzyme could be a potential drug target for B cell lymphomas

A metabolic enzyme could be a potential drug target for B cell lymphomas

CAR T Cell Therapy: Potential For Considerable Savings

CAR T Cell Therapy: Potential For Considerable Savings

A New Tool To Map The Flow Of Info Within Living Cells

A New Tool To Map The Flow Of Info Within Living Cells

Mouse model helps track organism’s development, cell by cell

Mouse model helps track organism’s development, cell by cell

Immune System Changes Occur Early In Development Of Multiple Myeloma

Immune System Changes Occur Early In Development Of Multiple Myeloma

A New Therapeutic Target Turns The Immune System Against Lymphoma

A New Therapeutic Target Turns The Immune System Against Lymphoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.